Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRED: Aspirin for Colorectal Cancer Risk Reduction
NCT02394769Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2015
- Primary completion
- Apr 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of aspirin in colorectal cancer (CRC) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Change in Urinary Prostaglandin Metabolites. Started Jul 2015; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02394769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02394769.